AMARIN CORP PLC\UK 10-Q

Item 5. Other Information No ne of our officers or directors, as defined in Rule 16a-1(f), adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K, during the three months ended September 30, 2025. 41 Item 6. Exhibits The following exhibits are incorporated by reference or filed or furnished as part of this report. Exhibit Number Description Incorporated by Reference Herein Form Date 4.1 Form of Second Amended and Restated Deposit Agreement among Amarin Corporation plc, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder, including the Form of ADR attached as Exhibit A thereto Registration Statement on Form F-6, Exhibit (a) July 23, 2025 10.1 Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated February 25, 2022*† Current Report on Form 8-K as Exhibit 10.1 October 22, 2025 10.2 First Amendment to the Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated July 17, 2023*† Current Report on Form 8-K as Exhibit 10.2 October 22, 2025 10.3 Second Amendment to the Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated October 6, 2025*† Current Report on Form 8-K as Exhibit 10.3 October 22, 2025 31.1 Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Certification of Vice President and Global Controller (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002 Filed herewith 32.1 Certification of President and Chief Executive Officer (Principal Executive Officer) and Vice President and Global Controller (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 906 of Sarbanes-Oxley Act of 2002 Filed herewith 101.SCH Inline XBRL Taxonomy Extension Schema Document Filed herewith 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Filed herewith 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document Filed herewith 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*) Filed herewith * Management contract or compensatory plan or arrangement. † Certain personal information in this exhibit has been omitted in accordance with Regulation S-K Item 601(a)(6). 42 SIGNA TURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AMARIN CORPORATION PLC By: /s/ Aaron Berg Aaron Berg President and Chief Executive Officer (Principal Executive Officer) (On behalf of the Registrant) Date: October 29, 2025 AMARIN CORPORATION PLC By: /s/ Peter Fishman Peter Fishman Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) (On behalf of the Registrant) Date: October 29, 2025 43